Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Hagens Berman Reminds Investors in Mednax, Inc. (NYSE: MD) of the September 10, 2018 Securities Class Action Lead Plaintiff Deadline

MD

SAN FRANCISCO, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP reminds investors in Mednax, Inc. (NYSE: MD) of the September 10, 2018 Lead Plaintiff deadline in the pending securities class action.  If you purchased or otherwise acquired Mednax securities between February 4, 2016 and July 27, 2017 and suffered losses contact Hagens Berman Sobol Shapiro LLP.  For more information visit:

https://www.hbsslaw.com/cases/MD

or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing

MD@hbsslaw.com.

On July 28, 2017, Defendants announced during Mednax’s second quarter earnings call with investors and analysts that (1) Mednax did not complete any acquisitions of anesthesiologist practices during the quarter, and (2) any future anesthesiologist acquisitions were unlikely.  This news appeared to be inconsistent with earlier statements that the Company had a robust pipeline of anesthesiologist deals.

This news drove the price of Mednax shares down $8.76, or over 15%, to close at $47.73 that day.

“We’re focused on investors’ losses and Defendants’ apparently misleading statements to Mednax investors about the sustainability of its acquisition-oriented business model,” said Hagens Berman partner Reed Kathrein.

Whistleblowers:  Persons with non-public information regarding Mednax should consider their options to help in the investigation or take advantage of the SEC Whistleblower program.  Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.  For more information, call Reed Kathrein at 510-725-3000 or email MD@hbsslaw.com.

About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with 80+ attorneys in 10 offices across the country.  The Firm represents investors, whistleblowers, workers and consumers in complex litigation.  More about the firm and its successes can be found at www.hbsslaw.com.  For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.

Contact:
Reed Kathrein, 510-725-3000

Primary Logo



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today